2M7C 주식 개요 중화인민공화국에서 의약품을 제조, 판매, 마케팅 및 홍보하는 투자 지주 회사인 China Medical System Holdings Limited는 의약품을 제조, 판매, 마케팅 및 홍보합니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
China Medical System Holdings Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 China Medical System Holdings 과거 주가 현재 주가 HK$0.89 52주 최고치 HK$1.52 52주 최저치 HK$0.71 베타 0.93 1개월 변경 0% 3개월 변경 사항 -4.81% 1년 변경 사항 -40.67% 3년 변화 -36.88% 5년 변화 -28.80% IPO 이후 변화 213.68%
최근 뉴스 및 업데이트
China Medical System Holdings Limited Announces First Prescription for Innovative Drug Lumeblue Issued in China Dec 09
China Medical System Holdings Limited Announces Approval of Drug Clinical Trials for Innovative Drug Nov 27
China Medical System Holdings Limited Announces New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong Nov 05
Insufficient new directors Nov 01
Investor sentiment improves as stock rises 15% Sep 30
China Medical System Holdings Limited Announces New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China Sep 24 더 많은 업데이트 보기
China Medical System Holdings Limited Announces First Prescription for Innovative Drug Lumeblue Issued in China Dec 09
China Medical System Holdings Limited Announces Approval of Drug Clinical Trials for Innovative Drug Nov 27
China Medical System Holdings Limited Announces New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong Nov 05
Insufficient new directors Nov 01
Investor sentiment improves as stock rises 15% Sep 30
China Medical System Holdings Limited Announces New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China Sep 24
Founder recently bought €415k worth of stock Aug 28
First half dividend of HK$0.16 announced Aug 19
First half 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.78 in 1H 2023) Aug 18
New minor risk - Profit margin trend Aug 16
China Medical System Holdings Limited Announces Re-Designation of Directors Aug 16 China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on About 9 September 2024
China Medical System Holdings Limited Announces NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China Aug 06
China Medical System Holdings Limited to Report First Half, 2024 Results on Aug 15, 2024 Aug 05
Now 25% undervalued after recent price drop Jul 01
China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China Jun 25
Founder recently bought €866k worth of stock Jun 19
Now 20% undervalued after recent price drop Jun 19
China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection Jun 18
Now 20% undervalued after recent price drop Jun 12
Founder recently bought €802k worth of stock May 26
Now 20% undervalued after recent price drop May 21
China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023 May 10
Upcoming dividend of HK$0.086 per share May 08
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China Apr 23
Now 21% undervalued after recent price drop Apr 15
Final dividend of HK$0.086 announced Apr 01
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024 Mar 30
New major risk - Share price stability Mar 29
Now 38% undervalued after recent price drop Mar 29
China Medical System Holdings Limited, Annual General Meeting, May 09, 2024 Mar 28
Full year 2023 earnings released: EPS: CN¥0.98 (vs CN¥1.33 in FY 2022) Mar 28
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024 Mar 27
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China Mar 20
China Medical System Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China Dec 12
China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application (Nda) for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China Dec 04
Upcoming dividend of HK$0.34 per share at 5.1% yield Sep 04
First half 2023 earnings released: EPS: CN¥0.78 (vs CN¥0.73 in 1H 2022) Aug 30
China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023 Aug 29
China Medical System Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023 Aug 18
New minor risk - Share price stability Aug 14
China Medical System Holdings Limited Receives Approval from National Medical Products Administration of China for New Drug Application of Diazepam Nasal Spray Jun 13
National Medical Products Administration of China Approves China Medical System Holdings's New Drug Application of Tildrakizumab Injection under the Brand Name of ILUMETRI May 31
Upcoming dividend of HK$0.27 per share at 4.7% yield Apr 26
Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021) Apr 06
Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021) Mar 17
China Medical System Holdings Limited Announces New Drug Application of Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Feb 16
China Medical System Holdings Limited Announces its Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Obtains Positive Results for its Phase III Clinical Trial in China Dec 20
Investor sentiment improved over the past week Dec 02
Upcoming dividend of HK$0.34 per share Aug 29
First half 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.66 in 1H 2021) Aug 24
China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 15 September 2022 Aug 23
China Medical System Holdings Limited to Report First Half, 2022 Results on Aug 22, 2022 Aug 11
China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021 Apr 23
Upcoming dividend of HK$0.28 per share Apr 19
Investor sentiment improved over the past week Mar 22
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 16
China Medical System Holdings Limited to Report Fiscal Year 2021 Results on Mar 15, 2022 Mar 06
China Medical System Holdings Limited Announces New Drug Application of Methotrexate Injection, Pre-Filled Syringe Accepted in China Dec 10
Independent Non-Executive Director Chi Keung Wu has left the company Oct 12
China Medical System Holdings Limited Establishes A New Programme with XF-73 Targeting the Prevention and Treatment of Superficial Skin Infections Caused by Bacteria Sep 29
Upcoming dividend of HK$0.32 per share Aug 30
First half 2021 earnings released: EPS CN¥0.66 (vs CN¥0.52 in 1H 2020) Aug 25
National Medical Products Grants Approval to China Medical System Holdings Limited's Methotrexate Injection, Pre-Filled Syringe Aug 14
China Medical System Holdings Limited Receives Approval for Innovative Patented Drug Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Aug 04
Investor sentiment deteriorated over the past week Jul 27
China Medical System Holdings Limited Announces That the Group's Innovative Drug Tildrakizumab Solution for Injection Obtained Positive Results of Its Phase Clinical Trial in China Jul 23
Investor sentiment deteriorated over the past week Jul 08
China Medical System Holdings Limited Announces New Drug Application of Diazepam Nasal Spray Accepted in China Jul 06
China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020 Apr 29
Upcoming dividend of HK$0.24 per share Apr 23
Full year 2020 earnings released: EPS CN¥1.02 (vs CN¥0.79 in FY 2019) Apr 04
Full year 2020 earnings released Mar 17 China Medical System Holdings Limited Recommends a Final Dividend for the Year Ended 31 December 2020, Payable About 10 May 2021
New 90-day high: €1.53 Mar 13
Investor sentiment improved over the past week Mar 13
China Medical System Holdings Limited to Report Fiscal Year 2020 Results on Mar 16, 2021 Mar 05
Investor sentiment deteriorated over the past week Feb 25
Investor sentiment improved over the past week Feb 04
China Medical System Holdings Limited (SEHK:867) acquired Luqa Ventures Co., Ltd. from third party sellers. Feb 02
New 90-day high: €1.11 Jan 22
Investor sentiment improved over the past week Jan 21
China Medical System Holdings Limited Announces Desidustat Tablets Being Granted an Approval for Drug Clinical Trial Jan 20
Investor sentiment improved over the past week Jan 09
New 90-day high: €0.98 Jan 07
Founder recently bought €2.4m worth of stock Dec 17
New 90-day low: €0.76 Dec 16
China Medical System Holdings Limited through its Wholly-Owned Subsidiary Signs License, Collaboration and Distribution Agreement with Cosmo Technologies Ltd Dec 06
New 90-day low: €0.85 Nov 26
New 90-day low: €0.91 Oct 24
New 90-day low: €0.92 Sep 29
China Medical System Holdings Limited Signs A Distribution, Supply and License Agreement (The "License Agreement"), with medac Gesellschaft für klinische Spezialpräparate mbH Sep 22
Founder recently bought €1.9m worth of stock Sep 05
New 90-day low - €0.93 Aug 29
First half earnings released Aug 29
First half earnings released Aug 13 주주 수익률 2M7C DE Pharmaceuticals DE 마켓 7D -0.6% -0.3% -0.3% 1Y -40.7% -17.0% 7.0%
전체 주주 수익률 보기
수익률 대 산업: 2M7C 지난 1년 동안 -17 %를 반환한 German Pharmaceuticals 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 2M7C 지난 1년 동안 7 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 2M7C's price volatile compared to industry and market? 2M7C volatility 2M7C Average Weekly Movement 6.5% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: 2M7C 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 2M7C 의 주간 변동성 ( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 투자 지주 회사인 차이나 메디컬 시스템 홀딩스는 중화인민공화국에서 의약품을 제조, 판매, 마케팅 및 홍보하는 회사입니다. 발작 군집 치료를 위한 디아제팜 비강 스프레이 발토코, 고혈압 및 안정형 협심증 치료제 플렌딜, 급성 심부전 치료제 신후오수, 경증에서 중등도 우울증, 불안 및 정신 신체적 정서를 위한 딘싯 등이 이 회사의 제품입니다; 난치성 장애성 건선 치료제 메토트렉세이트 주사제인 메토젝트, 담낭 내 콜레스테롤 담석, 담즙 정체성 간 질환 및 담즙 역류성 위염 치료제인 우르소포크 등이 있습니다. 또한 궤양성 대장염 및 크론병 치료제 살로포크, 설사 치료제 바이오플로, 소화불량 치료제 콤비자임, 중등도-중증 판상 건선 치료제 틸드라키주맙 주사제 일루메트리, 노인성 황반변성 및 무력증 치료제 어젠트로펜 스툴엔 모노 점안액, 혈종 및 표재성 정맥염을 동반한 둔상성 외상 치료제 히루도이드 등을 공급하고 있습니다.
자세히 보기 China Medical System Holdings Limited 기본 사항 요약 China Medical System Holdings 의 수익과 매출은 시가총액과 어떻게 비교하나요? 2M7C 기본 통계 시가총액 €2.25b 수익(TTM ) €183.04m 수익(TTM ) €923.43m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 2M7C 손익 계산서(TTM ) 수익 CN¥7.01b 수익 비용 CN¥1.85b 총 이익 CN¥5.17b 기타 비용 CN¥3.78b 수익 CN¥1.39b
주당 순이익(EPS) 0.58 총 마진 73.66% 순이익 마진 19.82% 부채/자본 비율 6.9%
2M7C 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/26 17:34 장 마감 주가 2024/12/23 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 China Medical System Holdings Limited 34 애널리스트 중 10 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Jessica Li BofA Global Research Lok Kwan Chiu CCB International Securities Limited Harry He China Galaxy International Securities (Hong Kong)
31 더 많은 분석가 보기 
